news:: Drug Discovery in Academia
Back to Drug Discovery in Academia

New Enterprise Associates

Robert Garland, M.D.
Robert joined NEA in 2003 and invests in biopharmaceuticals and medical devices. He is a director of 3-V Biosciences, Cardioxyl Pharmaceuticals, Trevena, Inc., and Zyngenia. Prior to NEA, in addition to clinical practice at the University of California, San Francisco (UCSF), he was with McKinsey & Company's Pharmaceutical & Medical Products and Corporate Finance & Strategy practices. At McKinsey, Robert worked with biotech, pharmaceutical, medical device, diagnostics, and private equity clients to evaluate investments, formulate product and corporate strategies and build businesses. Robert completed his Residency in Internal Medicine and Fellowship in Infectious Diseases at UCSF and received his MBA and MPH from the University of California, Berkeley, his MD from Baylor College of Medicine, and his BS in EE/Bioengineering from Rice University.

New Enterprise Associates (NEA)
NEA’s team of world-class investment professionals is deeply committed to helping our partner entrepreneurs and management teams build transformational companies. Our legacy of entrepreneurship—nearly one-third of our investing team members are former entrepreneurs of NEA—and unrivaled domain expertise in our sectors of focus make us an ideal partner for growing businesses.  When you choose to work with NEA, our team becomes your team—ready and able to take the call, answer the question, study the challenge and make a difference.

 
Share This Information